Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1001.92% is 18% above its 4-year average of -1222.95%, near the high end of its 4-year range (-206003.13%–57.38%).
97.78% above its 12-month average of -45137.24%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1750.20%.
EBITDA MARGIN
-1001.92%
EBITDA MARGIN AVG TTM
-45137.24%
EBITDA MARGIN AVG 3Y
-2121.50%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.78%
CURRENT VS 3Y AVG
+52.77%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
NewAmsterdam Pharma Company N.V.
Market Cap
$2.52B
EBITDA Margin
-1001.92%
TTM Avg
-45137.24%
3Y Avg
-2121.50%
5Y Avg
N/A
Market Cap
$2.57B
EBITDA Margin
2.08%
TTM Avg
1.74%
3Y Avg
1.01%
5Y Avg
-2.48%
Market Cap
$2.45B
EBITDA Margin
7.61%
TTM Avg
16.05%
3Y Avg
16.23%
5Y Avg
20.37%
Market Cap
$2.61B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$2.41B
EBITDA Margin
-4.36%
TTM Avg
-3.80%
3Y Avg
-12.43%
5Y Avg
-17.77%
Market Cap
$2.64B
EBITDA Margin
11.52%
TTM Avg
13.31%
3Y Avg
15.86%
5Y Avg
16.56%
Market Cap
$2.40B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$2.65B
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. (NAMS) | $2.52B | -1001.92% | -45137.24% | -2121.50% | N/A |
| Privia Health Group, Inc. (PRVA)vs › | $2.57B | 2.08% | 1.74% | 1.01% | -2.48% |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.45B | 7.61% | 16.05% | 16.23% | 20.37% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.61B | -270.04% | -444.88% | -365.27% | -89273.54% |
| Clover Health Investments, Corp. (CLOV)vs › | $2.41B | -4.36% | -3.80% | -12.43% | -17.77% |
| Disc Medicine, Inc. (IRON)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Neogen Corporation (NEOG)vs › | $2.64B | 11.52% | 13.31% | 15.86% | 16.56% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | -755.79% | -753.93% | -709.93% | -1157.85% |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.65B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.66B | 11.88% | 11.88% | 7.44% | -2.29% |
Gross Margin
92.2%
EBITDA Margin
-1001.9%
Operating Margin
-1002.9%
Net Margin
-3644.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1750.20% |
| 2026-03-31 | -1919.67% |
| 2025-12-31 | -206003.13% |
| 2025-09-30 | -15827.30% |
| 2025-06-30 | -185.90% |
| 2025-03-31 | -2312.73% |
| 2024-12-31 | -338.07% |
| 2024-09-30 | -85.79% |
| 2024-06-30 | -2306.10% |
| 2024-03-31 | -3921.20% |
| 2023-12-31 | -6358.78% |
| 2023-09-30 | -1684.60% |
| 2023-06-30 | -2473.44% |
| 2023-03-31 | -461.75% |
| 2022-12-31 | -509.83% |
| 2022-09-30 | -509.74% |
| 2022-06-30 | 57.38% |
| 2022-03-31 | 57.38% |
